All articles tagged with #amivantamab
Five Portuguese hospitals will enroll about 500 patients in a phase III trial of the injectable cancer drug amivantamab, given with immunotherapy every three weeks to treat untreated, incurable head and neck cancers; early ASCO results showed 43 responses (28 tumor shrinkages and 15 complete responses), driving hopes the treatment could become available in Portugal and possibly for other cancers in coming years.
In a 102-patient study of head and neck cancer, Johnson & Johnson’s amivantamab produced meaningful tumor responses in about 43 participants: 28 tumors shrank significantly and 15 dissolved, often within a week. Those treated had a median survival of roughly one year, despite difficult prognoses. The drug works by blocking EGFR and MET pathways and activating the immune system, with around 60 trials across lung, colorectal, brain and gastric cancers ongoing to evaluate its efficacy elsewhere.
An international trial of 102 patients with HPV-negative head and neck cancer found that amivantamab, a subcutaneously injected jab, shrank tumours in 43 patients and completely eradicated them in 15, including in cancers resistant to chemotherapy and immunotherapy. The triple-action antibody blocks EGFR and MET and stimulates the immune system, and showed manageable side effects with most patients able to continue treatment; median overall survival was 12.5 months. The drug is also being explored in other cancers and results were to be presented at ASCO.
In a multi-country trial, Johnson & Johnson’s amivantamab shrank or eradicated tumors in patients with head and neck cancer (and some lung cancers) that had stopped responding to chemotherapy or immunotherapy; 43 of 102 patients responded (28 partial shrinkages, 15 complete disappearances), with results to be presented at ASCO in Chicago; the drug works by targeting tumor growth proteins and activating the immune system, and median survival was about 12.5 months, with ongoing trials to explore broader use.
A former Ironman triathlete’s vision problems led doctors to diagnose stage 4 lung cancer, and after a sequence of targeted therapies—including afatinib, osimertinib, and the IV drug amivantamab (Rybrevant)—he has lived seven years beyond an initial 12–24 month prognosis and now raises awareness through advocacy and endurance events.